Full Press Release Details
Powered and protected by
Privacy
INCY Neutral Sentiment Score: 50/100
Samenvatting: De resultaten van Incyte’s cruciale fase 3-studie frontMIND naar de combinatiebehandeling met tafasitamab (Monjuvi® /Minjuvi®) werden gepresenteerd tijdens de plenaire sessie van het congres van de European Hematology Association (EHA)...
Key Takeaway: Incyte's phase 3 study results for the combination treatment with tafasitamab were presented at the European Hematology Association congress. The details of the findings and their implications for treatment were discussed during the plenary session.